231 related articles for article (PubMed ID: 29669531)
1. Assessment of an optimized manufacturing process for inactivated quadrivalent influenza vaccine: a phase III, randomized, double-blind, safety and immunogenicity study in children and adults.
Claeys C; Drame M; García-Sicilia J; Zaman K; Carmona A; Tran PM; Miranda M; Martinón-Torres F; Thollot F; Horn M; Schwarz TF; Behre U; Merino JM; Sadowska-Krawczenko I; Szymański H; Schu P; Neumeier E; Li P; Jain VK; Innis BL
BMC Infect Dis; 2018 Apr; 18(1):186. PubMed ID: 29669531
[TBL] [Abstract][Full Text] [Related]
2. Safety, immunogenicity, and lot-to-lot consistency of a split-virion quadrivalent influenza vaccine in younger and older adults: A phase III randomized, double-blind clinical trial.
Sesay S; Brzostek J; Meyer I; Donazzolo Y; Leroux-Roels G; Rouzier R; Astruc B; Szymanski H; Toursarkissian N; Vandermeulen C; Kowalska E; Van Damme P; Salamand C; Pepin S
Hum Vaccin Immunother; 2018 Mar; 14(3):596-608. PubMed ID: 28968138
[TBL] [Abstract][Full Text] [Related]
3. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial.
Cadorna-Carlos JB; Nolan T; Borja-Tabora CF; Santos J; Montalban MC; de Looze FJ; Eizenberg P; Hall S; Dupuy M; Hutagalung Y; Pépin S; Saville M
Vaccine; 2015 May; 33(21):2485-92. PubMed ID: 25843270
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8 y of age: A phase III randomized controlled study.
Pepin S; Szymanski H; Rochín Kobashi IA; Villagomez Martinez S; González Zamora JF; Brzostek J; Huang LM; Chiu CH; Chen PY; Ahonen A; Forstén A; Seppä I; Quiroz RF; Korhonen T; Rivas E; Monfredo C; Hutagalung Y; Menezes J; Vesikari T
Hum Vaccin Immunother; 2016 Dec; 12(12):3072-3078. PubMed ID: 27565435
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial.
Chang LJ; Meng Y; Janosczyk H; Landolfi V; Talbot HK;
Vaccine; 2019 Sep; 37(39):5825-5834. PubMed ID: 31431411
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of a quadrivalent inactivated influenza virus vaccine compared with a comparator quadrivalent inactivated influenza vaccine in a pediatric population: A phase 3, randomized noninferiority study.
Airey J; Albano FR; Sawlwin DC; Jones AG; Formica N; Matassa V; Leong J
Vaccine; 2017 May; 35(20):2745-2752. PubMed ID: 28390934
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in children 6-59 months of age: A phase 3, randomized, noninferiority study.
Statler VA; Albano FR; Airey J; Sawlwin DC; Graves Jones A; Matassa V; Heijnen E; Edelman J; Marshall GS
Vaccine; 2019 Jan; 37(2):343-351. PubMed ID: 30057283
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study.
Treanor JT; Albano FR; Sawlwin DC; Graves Jones A; Airey J; Formica N; Matassa V; Leong J
Vaccine; 2017 Apr; 35(15):1856-1864. PubMed ID: 28302411
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of a quadrivalent intradermal influenza vaccine in adults.
Gorse GJ; Falsey AR; Ozol-Godfrey A; Landolfi V; Tsang PH
Vaccine; 2015 Feb; 33(9):1151-9. PubMed ID: 25613721
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18-60 years of age in the Republic of Korea.
Choi WS; Noh JY; Lee J; Choi JY; Lee JS; Kim MS; Kim HS; Bang J; Lavis N; Kim WJ
Hum Vaccin Immunother; 2018 Mar; 14(3):587-592. PubMed ID: 28933625
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: A randomized, double-blind, controlled phase III study in healthy population aged ≥3 years.
Chu K; Xu K; Tang R; Tian X; Hu J; Yang T; Li C; Hu Y; Zeng G
Vaccine; 2020 Aug; 38(37):5940-5946. PubMed ID: 32732142
[TBL] [Abstract][Full Text] [Related]
12. Time to Change Dosing of Inactivated Quadrivalent Influenza Vaccine in Young Children: Evidence From a Phase III, Randomized, Controlled Trial.
Jain VK; Domachowske JB; Wang L; Ofori-Anyinam O; Rodríguez-Weber MA; Leonardi ML; Klein NP; Schlichter G; Jeanfreau R; Haney BL; Chu L; Harris JS; Sarpong KO; Micucio AC; Soni J; Chandrasekaran V; Li P; Innis BL
J Pediatric Infect Dis Soc; 2017 Mar; 6(1):9-19. PubMed ID: 28062552
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65 y of age and older.
Greenberg DP; Robertson CA; Talbot HK; Decker MD
Hum Vaccin Immunother; 2017 Sep; 13(9):2058-2064. PubMed ID: 28700265
[TBL] [Abstract][Full Text] [Related]
14. Anamnestic Immune Response and Safety of an Inactivated Quadrivalent Influenza Vaccine in Primed Versus Vaccine-Naïve Children.
Claeys C; Chandrasekaran V; García-Sicilia J; Prymula R; Díez-Domingo J; Brzostek J; Marès-Bermúdez J; Martinón-Torres F; Pollard AJ; Růžková R; Carmona Martinez A; Ulied A; Miranda Valdivieso M; Faust SN; Snape MD; Friel D; Ollinger T; Soni J; Schuind A; Li P; Innis BL; Jain VK
Pediatr Infect Dis J; 2019 Feb; 38(2):203-210. PubMed ID: 30325891
[TBL] [Abstract][Full Text] [Related]
15. Superior immunogenicity of high-dose quadrivalent inactivated influenza vaccine versus Standard-Dose vaccine in Japanese Adults ≥ 60 years of age: Results from a phase III, randomized clinical trial.
Sanchez L; Nakama T; Nagai H; Matsuoka O; Inoue S; Inoue T; Shrestha A; Pandey A; Chang LJ; De Bruijn I;
Vaccine; 2023 Apr; 41(15):2553-2561. PubMed ID: 36906404
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, immunogenicity, and safety of a quadrivalent inactivated influenza vaccine in children aged 6-35 months: A multi-season randomised placebo-controlled trial in the Northern and Southern Hemispheres.
Pepin S; Dupuy M; Borja-Tabora CFC; Montellano M; Bravo L; Santos J; de Castro JA; Rivera-Medina DM; Cutland C; Ariza M; Diez-Domingo J; Gonzalez CD; Martinón-Torres F; Papadopoulou-Alataki E; Theodoriadou M; Kazek-Duret MP; Gurunathan S; De Bruijn I;
Vaccine; 2019 Mar; 37(13):1876-1884. PubMed ID: 30558818
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults ≥50years of age: Results from a phase III, randomized, non-inferiority trial.
Ofori-Anyinam O; Leroux-Roels G; Drame M; Aerssens A; Maes C; Amanullah A; Schuind A; Li P; Jain VK; Innis BL
Vaccine; 2017 Nov; 35(46):6321-6328. PubMed ID: 28987445
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of high doses of quadrivalent influenza vaccine in children 6 months through <18 years of age: A randomized controlled phase II dose-finding trial.
Chang LJ; Anderson EJ; Jeanfreau R; He Y; Hicks B; Shrestha A; Pandey A; Landolfi V; DeBruijn I;
Vaccine; 2021 Mar; 39(11):1572-1582. PubMed ID: 33610374
[TBL] [Abstract][Full Text] [Related]
19. Safety and Immunogenicity of a Full-dose, Split-virion, Inactivated, Quadrivalent Influenza Vaccine in Healthy Children 6-35 Months of Age: A Randomized Controlled Clinical Trial.
Robertson CA; Mercer M; Selmani A; Klein NP; Jeanfreau R; Greenberg DP
Pediatr Infect Dis J; 2019 Mar; 38(3):323-328. PubMed ID: 30395011
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of high-dose quadrivalent influenza vaccine in Japanese adults ≥65 years of age: a randomized controlled clinical trial.
Sanchez L; Matsuoka O; Inoue S; Inoue T; Meng Y; Nakama T; Kato K; Pandey A; Chang LJ
Hum Vaccin Immunother; 2020 Apr; 16(4):858-866. PubMed ID: 31634025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
